M&A Sparks Biotechs: Alexion Buys Synageva For $8.4B…Update-1

An issue for rare disease companies down the road is pricing as government agencies may question spending hundreds of thousands of dollars per year for one patient. But the number of patients are very small in the 10,000 range...